SALT629
SALT629 is an orally active antitubercular agent with potent intramacrophage activity (EC50 = 1.5 μM). sALT629 shows broad-spectrum anti-Mycobacterium tuberculosis (Mtb) activities across four carbon sources, equipotent efficacy against drug-resistant Mtb, and activity against both slow-replicating and nonreplicating Mtb. sALT629 exhibits synergistic activity when combined with oxazolidinone drugs, such as Linezolid and Sutezolid (HY-10392). sALT629 can be used for the research of tuberculosis[1].
Product Specifications
CAS Number
484026-63-3
UNSPSC
12352005
Target
Bacterial
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Smiles
O=C(CN1N=NC(C2=CC=C(C=C2)OCC(C)C)=N1)N
Molecular Formula
C13H17N5O2
Molecular Weight
275.31
References & Citations
[1]Yang B, et al. Design, Synthesis, and Biological Evaluation of Tetrazol-2-yl-acetamides as Novel Antitubercular Agents. ACS Med Chem Lett. 2025 Nov 21;16 (12) :2444-2453.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
30-2326-100 100 Tests
PE Conjugated Anti-Kappa light chains Monoclonal Antibody (Clone:TB28-2)
Sign In for Pricing
View Details 
E51K2761 40 µL
TUBA1B/TUBA4A Rabbit Monoclonal Antibody [KD Validation]
Sign In for Pricing
View Details